![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Background: It is important to determine the vasoconstrictor potencies of topical corticosteroids used to treat psoriasis to ensure appropriate clinical use.
Objective: To compare the vasoconstrictive potencies of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) (Cal/BD) cutaneous foam with other topical corticosteroids.
Methods: In this Phase I, single-center, healthy volunteer study, Cal/BD foam, clobetasol propionate 0.05% cream (CP; very potent), BD 0.05% ointment (potent), mometasone furoate 0.1% cream (MF; potent), hydrocortisone-17-butyrate 0.1% ointment (HB; moderately potent), and foam vehicle were applied, then removed after 16 h. Skin blanching was visually assessed 2 h later (scale of 0–4).
Results: Thirty-six volunteers were randomized. Skin blanching with Cal/BD foam (median [range], 2.00 [0.75–3.00]) was significantly lower than CP cream (3.00 [1.75–4.00]; p < .001), was not significantly different from BD ointment (1.75 [0.75–3.00]; p = .30) and MF cream (2.00 [1.00–3.75]; p = .22), and was significantly greater than HB ointment (1.25 [0.50–3.00]; p < .001) and vehicle (0 [0–0.50]; p < .001). There were no local tolerability reactions or adverse events.
Conclusions: The corticosteroid potency of Cal/BD foam was not significantly different from BD ointment and MF cream, significantly stronger than HB ointment, but weaker than CP cream in healthy volunteers.
Previous presentation
Poster presented at the 26th EADV Congress, Geneva, Switzerland, September 13–17 2017.
Disclosure statement
C. Queille-Roussel reports subject fees paid by LEO Pharma; J. Nielsen is an employee of LEO Pharma; J.-P. Lacour reports reimbursement for conference attendance and honoraria for consultancy activity from LEO Pharma.